Saturday, November 21, 2026
RSS

Pharmaceutical

Oruka Therapeutics Insider Sale Puts Clinical-Stage Biotech Sentiment Under the Microscope

Oruka’s $853,985 insider sale draws attention as traders weigh the transaction against positive EVERLAST-B Phase trial results.

November 21, 2026
Pharmaceutical
Pharmaceutical
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.


Pharmaceutical

PMV Pharmaceuticals’ Updated Rezatapopt Data Puts Precision Oncology Back in Focus

PMV Pharmaceuticals’ updated PYNNACLE Phase 2 data gives investors a closer look at rezatapopt and i…

Nov 20, 2026
Pharmaceutical

Revolution Medicines Defies Market Selloff as Survival Data Lift RVMD

RVMD traded higher as survival data, a $226 William Blair target and new Phase 3 treatment activity …

Nov 20, 2026
Pharmaceutical

Belite Bio Slides 12% as FDA Extends Tinlarebant Review

Belite Bio shares fell 12% after the FDA extended its tinlarebant review by three months, resetting …

Nov 20, 2026
Pharmaceutical

Savara Shares Slip After FDA Delays Autoimmune PAP Decision

Savara’s missed FDA target date leaves investors facing a longer wait for clarity on its autoimmune …

Nov 20, 2026
Pharmaceutical

Revolution Medicines Rallies on Clinical Data as Biotech Decouples From Weak Market

Revolution Medicines showed premarket relative strength as clinical data offset a 1.0% S&P 500 decli…

Nov 20, 2026
Pharmaceutical

Capricor Therapeutics Defies Market Selloff as Traders Position for FDA Catalyst

CAPR rallied in premarket trading as the Nasdaq and S&P 500 declined, putting the biotech’s FDA cata…

Nov 20, 2026
Pharmaceutical

Alnylam’s $25 Million Regeneron Milestone Puts Its RNAi Model in Focus

Alnylam’s $25 million Livsayis milestone highlights the commercial value of its RNAi platform and pa…

Nov 19, 2026
Pharmaceutical

Black Diamond Gains as FDA Maps Accelerated-Approval Path for Silevertinib

FDA guidance on accelerated approval and a broad EGFR mutation definition may reduce uncertainty aro…

Nov 19, 2026
Pharmaceutical

J&J Seeks FDA Approval to Expand CAPLYTA Into Bipolar Mania

J&J’s CAPLYTA filing could create a fifth potential indication, broadening its psychiatric franchise…

Nov 19, 2026